RH (NYSE: RH ) stock has been a difficult holding for quite some time, especially for those who bought in 2021. The stock has underperformed significantly compared to the general S&P 500 index since the end ofI am a dedicated financial risk manager and investor specializing in financials, consumer, and technology industries. I have been involved in the investing world for over seven years, making deep analyses and managing different types of portfolios.I believe in deep research, prioritizing business model ...

Company Performance - RH's stock closed at $184.14, showing a slight increase of +0.16% from the previous day, but underperformed compared to the S&P 500's gain of 0.4% [1] - Over the past month, RH's shares experienced a loss of 0.1%, lagging behind the Consumer Staples sector's gain of 1.13% and the S&P 500's gain of 6.69% [1] Earnings Forecast - The upcoming earnings report for RH is expected to show an EPS of -$0.09, which represents a significant increase of 77.5% compared to the same quarter last year [2] - Revenue is forecasted to be $818.86 million, indicating a growth of 12.64% year-over-year [2] Full Year Projections - For the full year, earnings are projected at $10.74 per share and revenue at $3.53 billion, reflecting increases of +99.26% and +11.08% respectively from the previous year [3] - Recent adjustments to analyst estimates for RH indicate a positive outlook, suggesting optimism regarding the company's business and profitability [3] Valuation Metrics - RH's current Forward P/E ratio stands at 17.12, which is lower than the industry average Forward P/E of 20.29, indicating a potential valuation discount [6] - The company has a PEG ratio of 0.55, significantly lower than the Consumer Products - Staples industry's average PEG ratio of 3.52, suggesting favorable growth expectations relative to its valuation [7] Industry Context - The Consumer Products - Staples industry, which includes RH, has a Zacks Industry Rank of 171, placing it in the bottom 31% of over 250 industries [8] - Historical data shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1, highlighting the competitive landscape within the sector [8]

智通财经APP获悉，5月21日，罗氏(RHHBY.US)宣布III期TALENTACE研究达到主要研究终点，该研究 评估了阿替利珠单抗、贝伐珠单抗和按需经动脉化疗栓塞术（TACE）在未接受过既往全身系统治疗的 不可切除肝细胞癌（HCC）患者中的疗效和安全性。 该研究显示，主要终点TACE 无进展生存期（TACE-PFS，从随机分组到研究者评估的TACE不可治疗 进展或TACE失败/抵抗或任何原因死亡的时间）取得了统计学和临床意义上的显著改善，中期分析时总 生存期（OS）尚不成熟。同时，由RECIST v1.1评估的PFS也观察到了有临床意义的改善。 TALENTACE研究开创性地探索了免疫检查点抑制剂阿替利珠单抗联合抗血管生成靶向治疗贝伐珠单抗 与按需TACE同期联合治疗的协同效应。同时，TALENTACE研究创新性地将TACE-PFS作为主要终 点，并在未经系统治疗的中高肿瘤负荷HCC 患者中显示出治疗获益，有望为肝癌局部肿瘤控制与系统 分子干预的联合治疗模式提供高级别循证依据。研究数据分析显示，阿替利珠单抗和贝伐珠单抗的安全 性特征与先前的数据和基础疾病一致。 罗氏制药中国医学事务副总裁李滨博士表示，他们 ...

Company Performance - RH's stock closed at $207.52, reflecting a +1.77% increase from the previous trading day's closing, outperforming the S&P 500's loss of 0.39% [1] - Over the past month, RH's shares gained 30.89%, significantly outperforming the Consumer Staples sector, which saw a loss of 0.12% [1] Earnings Expectations - The upcoming earnings report for RH is expected to show an EPS of -$0.09, representing a 77.5% increase compared to the same quarter last year [2] - Revenue is anticipated to reach $818.86 million, marking a 12.64% increase year-over-year [2] Full-Year Estimates - Zacks Consensus Estimates project RH's full-year earnings at $10.72 per share and revenue at $3.53 billion, indicating year-over-year growth of +98.89% and +11.08%, respectively [3] - Recent analyst estimate revisions for RH suggest positive sentiment regarding the company's business and profitability [3][4] Valuation Metrics - RH's current Forward P/E ratio is 19.01, which is lower than the industry average of 20.36 [6] - The PEG ratio for RH stands at 0.61, compared to the average PEG ratio of 3.57 for Consumer Products - Staples stocks [6] Industry Context - The Consumer Products - Staples industry, which includes RH, ranks 166 in the Zacks Industry Rank, placing it in the bottom 33% of over 250 industries [7] - The top 50% rated industries tend to outperform the bottom half by a factor of 2 to 1, indicating potential challenges for RH within its industry context [7]

APHINITY(NCT01358877/BO25126/BIG4-11)是一项全球性III期、随机、双盲、安慰剂对照、双组研 究，旨在评估帕妥珠单抗联合赫赛汀联合化疗作为术后(辅助)治疗的疗效和安全性，并与赫赛汀联合化 疗进行比较。 该研究在4804名可手术治疗的HER2阳性早期乳腺癌患者中开展。研究的主要终点是无浸润性疾病生存 期，次要终点包括心脏和总体安全性、总体生存期和健康相关生活质量。 5月13日，罗氏(RHHBY.US)公布III期APHINITY研究的最终总生存期(OS)结果，该研究针对HER2阳性 早期乳腺癌患者。十年后的研究结果显示，研究达到统计学意义：与接受赫赛汀、化疗和安慰剂治疗的 患者相比，接受帕妥珠单抗(Perjeta)、赫赛汀(曲妥珠单抗)和化疗作为术后(辅助)治疗的患者，死亡风险 降低了17%。 在预设的淋巴结阳性患者亚组中，死亡风险降低了21%(HR=0.79，95%CI：0.64-0.97)。 先前APHINITY分析报告的无侵袭性疾病生存期(主要终点)获益得到了维持(HR=0.79，95%CI：0.68- 0.92)。在淋巴结阴性亚组中未观察到获益。 包括心脏安全性在内的安 ...

Moretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with durable business models, mispriced cash flow potential, and intelligent capital allocation. Built on institutional standards, Moretus Research combines rigorous fundamental analysis with a high-signal, judgment-driven process—eschewing noise, narrative, and overl ...

RH (RH) closed at $182.87 in the latest trading session, marking a -1.85% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.77%. Elsewhere, the Dow saw a downswing of 0.95%, while the tech-heavy Nasdaq depreciated by 0.87%.Heading into today, shares of the furniture and housewares company had gained 13.27% over the past month, outpacing the Consumer Staples sector's gain of 2.17% and the S&P 500's gain of 11.54% in that time.Investors will be eagerly watching for the ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RH (NYSE: RH) for potential violations of the federal securities laws. If you invested in RH, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/rh. Why is RH being Investigated? RH is a retailer and luxury lifestyle brand operating primarily in the home furnishings market that offers merchandise assortments across a numbe ...

NEW YORK, May 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into RH (NYSE: RH) for potential violations of the federal securities laws. If you invested in RH, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/rh. Why is RH being Investigated? RH is a retailer and luxury lifestyle brand operating primarily in the home furnishings market that offers merchandise assortments across a numbe ...

It has been about a month since the last earnings report for RH (RH) . Shares have added about 23.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is RH due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.How Have Estimates Been Moving Since Then?It turns out, estimates r ...